Literature DB >> 3084247

Correlation of predicted serum bactericidal activities and values measured in volunteers.

G Drusano, H Standiford, P Ryan, W McNamee, B Tatem, S Schimpff.   

Abstract

A method was devised for predicting the serum bactericidal activity of new drugs. Six healthy volunteers received 2 g moxalactam, cefoperazone and cefotaxime, respectively, as 30-min infusions in a crossover manner at one-week intervals. The pharmacokinetics of each drug was characterized and the bactericidal activity of the serum 1 h after infusion was measured against panels of six strains of Pseudomonas aeruginosa, six strains of Escherichia coli, six strains of Staphylococcus aureus, and four strains of Klebsiella pneumoniae. The minimum bactericidal concentration of each antibiotic was determined for each organism by the standard NCCLS reference method and the method of Stratton and Reller. On the basis of these values and a serum concentration-time curve constructed from individual patient pharmacokinetic parameters, the bactericidal activity of the serum 1 h after infusion was predicted. These predictions showed a 90% agreement with measured values calculated according to the method of Stratton and Reller, whereas an agreement of 74% was obtained with the reference method. This difference was statistically significant (p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3084247     DOI: 10.1007/bf02013475

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  7 in total

Review 1.  Molecular structure of bacterial plasmids.

Authors:  R C Clowes
Journal:  Bacteriol Rev       Date:  1972-09

2.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

3.  Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.

Authors:  H C Standiford; G L Drusano; W B McNamee; B Tatem; P A Ryan; S C Schimpff
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

4.  Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent.

Authors:  C W Stratton; L B Reller
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

5.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

6.  Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration.

Authors:  C W Stratton; M P Weinstein; L B Reller
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

7.  Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.

Authors:  R Platt; S L Ehrlich; J Afarian; T F O'Brien; J E Pennington; E H Kass
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

  7 in total
  16 in total

1.  Antibacterial properties of gemifloxacin and trovafloxacin in urine ex vivo: phase I study.

Authors:  G García-Calvo; A Parra; L Aguilar; C Ponte; M J Giménez; A Carcas; M Kinzig-Schippers; F Soriano
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Effect of ertapenem protein binding on killing of bacteria.

Authors:  David E Nix; Kathryn R Matthias; Emily C Ferguson
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

3.  Effects of supraphysiologic temperature and broth dilution on serum protein binding.

Authors:  R L White; M B Kays; T A Armstrong; L V Friedrich
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 4.  Standardization of the serum bactericidal test and its relationship to levels of antimicrobial agents.

Authors:  C W Stratton
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 5.  Role of pharmacokinetics in the outcome of infections.

Authors:  G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1988-03       Impact factor: 5.191

Review 6.  Seventy-Five Years of Research on Protein Binding.

Authors:  Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

7.  Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities.

Authors:  L Aguilar; M J Giménez; J Costa; R Dal-Ré; J Prieto
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

8.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.

Authors:  J M Hyatt; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

10.  Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.

Authors:  P Van der Auwera; V Duchateau; C Lambert; M Husson; M Kinzig; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.